Tempest Therapeutics Shareholder Meeting
Tempest Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders elected two Class II directors and ratified Ernst & Young LLP as the independent auditor. Stockholders also approved two key financing-related proposals under Nasdaq rules, including the potential issuance of shares to Lincoln Park Capital Fund and shares issuable upon the exercise of warrants from a September 2026 private placement.